Strand Therapeutics
PrivateLast Round
Series B
Mar 17, 2026
Est. Valuation
$550M
Total Funding Raised
$266M
Company Overview
Strand Therapeutics is a biotechnology company that develops programmable, long-acting mRNA therapeutics designed to deliver precise, multi-functional treatments for cancer and autoimmune diseases.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials, Precision Medicine
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Application
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Strand Therapeutics Comparables
Compare Strand Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Kernalbio | 84% | |
| Bristol Myers Squibb | 84% | |
| Replicate Bioscience | 82% |
Strand Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series B | Mar 17, 2026 | ||||
| Series B | Aug 7, 2025 | ||||
| Series A Extension | Nov 28, 2022 | ||||
| Series A | Jun 23, 2021 | ||||
| Corporate Funding | Jan 11, 2021 | ||||
Seed | Jun 4, 2019 |
Key People
Founding team and executive leadership
Strand Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Redmile Group | Series A |
| Alderline Group | Series B |
| ICONIQ Capital | Series B |
| Camford Capital | Series A |
| Playground Global | Series B, Series A Extension, Series A, Seed |
| LG Technology Ventures | Series B |
| ANRI株式会社 | Series B, Seed, Series A |
Market signals
Structured signals derived from secondary market and firmographic data.
- Mar 1, 2026
Lead program STX-001 now in Phase 1 trial for solid tumors.
- Aug 23, 2025
Dr. Jason J. Luke appointed as new Chief Medical Officer.
Strand Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about Strand Therapeutics's valuation, stock price, and market status.
Is Strand Therapeutics a public or private company?
Strand Therapeutics is a private company.
What is the current stock price of Strand Therapeutics?
Strand Therapeutics is a private company with no public stock price. No recent secondary market data is available.
How much is Strand Therapeutics worth (valuation)?
Strand Therapeutics's valuation is estimated at $550.0M based on funding round data.
Can I buy Strand Therapeutics stock?
Strand Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.
When was Strand Therapeutics's last funding round?
Strand Therapeutics's most recent funding round was Series B on August 7, 2025.
Who are the main investors in Strand Therapeutics?
Key investors in Strand Therapeutics include Redmile Group, Playground Global, FPV Ventures, Kinnevik.
Will Strand Therapeutics IPO soon?
No public IPO plans have been announced for Strand Therapeutics.
How can I track Strand Therapeutics secondary market activity?
Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Strand Therapeutics's secondary market activity and sign up for updates.